Pieris Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 2.78 million compared to USD 2.58 million a year ago. Revenue was USD 4.06 million compared to USD 2.94 million a year ago. Net loss was USD 16.54 million compared to USD 14.28 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.26 a year ago. For the nine months, sales was USD 20.19 million compared to USD 22.39 million a year ago. Revenue was USD 22.98 million compared to USD 27.45 million a year ago. Net loss was USD 36.21 million compared to USD 22.83 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.42 a year ago.